文献速递胸部肿瘤

克唑替尼对比化疗一线治疗ALK阳性非小细胞肺癌的最终总生存分析

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2018-05-16

Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results.…

要点

  • 克唑替尼组中位OS未达到(95%CI 45.8个月-NR),化疗组47.5个月(95%CI 32.2-NR)。
  • 交叉调整后HR 0.346(95% bootstrap CI 0.081-0.718),支持克唑替尼改善OS。

核心结论

  • 最终分析为ALK重排NSCLC患者的总生存提供了新基准,并强调克唑替尼延长该人群生存的获益。

研究设计与样本

  • III期PROFILE 1014试验随机分配患者至口服克唑替尼250 mg每日两次组(n=172)或静脉培美曲塞500 mg/m2联合顺铂75 mg/m2或卡铂(AUC 5-6 mg·mL/min)每3周最多6周期组(n=171)。
  • 疾病进展后允许交叉至克唑替尼,OS采用分层log-rank检验和预设的秩保持结构失效时间模型分析。

主要发现

  • 两组OS中位随访约46个月,化疗组144例(84.2%)后续接受克唑替尼。
  • 克唑替尼组中位OS未达到(95%CI 45.8个月-NR),化疗组为47.5个月(95%CI 32.2个月-NR)。
  • 4年生存概率克唑替尼组56.6%(95%CI 48.3%-64.1%),化疗组49.1%(95%CI 40.5%-57.1%)。
  • 交叉调整后OS改善 favoring克唑替尼(风险比0.346;95% bootstrap CI 0.081-0.718),未发现新安全性信号。

关键数值与推荐

  • 交叉调整后风险比0.346(95% bootstrap CI 0.081-0.718)。
  • 4年生存概率:克唑替尼56.6%(95%CI 48.3%-64.1%),化疗49.1%(95%CI 40.5%-57.1%)。

临床怎么用

  • 克唑替尼可作为ALK阳性晚期非鳞NSCLC的一线治疗选择,后续接受ALK TKI与最长OS相关。

局限性

  • 化疗组84.2%患者交叉接受克唑替尼,可能稀释未调整OS的组间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin (area under the concentration-time curve of 5 to 6 mg·mL/min) every 3 weeks for a maximum of six cycles (n = 171). Crossover to crizotinib was permitted after disease progression. OS was analyzed using a stratified log-rank test and a prespecified rank-preserving structural failure time model to account for crossover. Results Median follow-up duration for OS was approximately 46 months for both arms. In the chemotherapy arm, 144 patients (84.2%) received crizotinib in subsequent lines. Hazard ratio for OS was 0.760 (95% CI, 0.548 to 1.053; two-sided P = .0978). Median OS was not reached (NR) with crizotinib (95% CI, 45.8 months to NR) and 47.5 months with chemotherapy (95% CI, 32.2 months to NR). Survival probability at 4 years was 56.6% (95% CI, 48.3% to 64.1%) with crizotinib and 49.1% (95% CI, 40.5% to 57.1%) with chemotherapy. After crossover adjustment, there was an improvement in OS that favored crizotinib (hazard ratio, 0.346; 95% bootstrap CI, 0.081 to 0.718). The longest OS was observed in crizotinib-treated patients who received a subsequent ALK tyrosine kinase inhibitor. No new safety signals were identified. Conclusion The final analysis of the PROFILE 1014 study provides a new benchmark for OS in patients with ALK-rearranged non-small-cell lung cancer and highlights the benefit of crizotinib for prolonging survival in this patient population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29768118. doi:10.1200/JCO.2017.77.4794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。